IL6 and congenital rubella syndrome: This CAR-T product has been shown to reduce the incidence of IL-6 and IL-1-related CRS and ICANS by secreting anti-IL6 scFv and IL1 receptor antagonist (IL1RA), which could self-neutralize IL-6 and IL-1 in serum (41).